Guotai Junan International maintains a "buy" rating on Kangji Pharmaceutical (00867.HK), exclusive and innovative products become new growth drivers.

Zhixin Finance APP learned that CICC International released a research report stating that it has adjusted its profit forecast, predicting that the attributable net profit of Kangzhe Pharmaceutical (00867.HK) for 2025-2027 will be 16.61 billion yuan, 19.17 billion yuan, and 22.72 billion yuan, with year-on-year growth of 2.54%, 15.39%, and 18.57% respectively. Corresponding to the closing price on September 11, 2025, the PE ratios are 20.06, 17.39, and 14.66 times, maintaining a "buy" rating.